Mumbai: Cardiac device maker S3V Vascular Technologies Limited has announced plans to move its indigenously developed Balloon-Expandable Transcatheter Aortic Valve Replacement (TAVR) system into preclinical study.
Preclinical evaluation will validate its safety and design performance. Pending successful clinical trials and regulatory approvals, the company aims for a commercial launch within the next 12 to 18 months.
TAVR is a minimally invasive therapy for patients with severe aortic stenosis. While traditional treatment requires open-heart surgery, TAVR allows clinicians to replace the valve via a catheter, significantly reducing recovery time for elderly or high-risk patients.
According to the company, existing valve replacement systems which are imported in India cost between ₹13 lakh and ₹23 lakh, making them highly inaccessible for many Indian patients.
S3V aims to significantly reduce the treatment costs by providing a high-quality, locally developed alternative.
“This launch represents a vital step toward democratising advanced cardiac care, ” said Dr. Vijaya Gopal, Managing Director of S3V Vascular Technologies Limited. “Our vision is to make life-saving structural heart therapies accessible to the broader population by reducing device costs through domestic innovation.”
